China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE: 000999)
Health Care · Pharmaceuticals · CN
CN¥24.14
-3.67% today · -21.4% 1Y
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE: 000999) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.98B and employs 30,304 people.
Over the last twelve months the share price has lost 21.4%, trading between 21.60 and 31.05.
Tweenvest scores China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. across four factors: quality 86/100, value 79/100, growth 77/100, dividend 77/100. Its strongest factor is quality.
000999 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.98B
- Revenue (TTM)
- $4.68B
- P/E
- 12.26
- EPS
- 1.97
- Dividend yield
- 4.15%
- Beta (5Y)
- -0.01
- 52-week high
- CN¥31.05
- 52-week low
- CN¥21.60
- Avg volume (3M)
- —
- Shares outstanding
- 1.66B
- Employees
- 30,304
- Next earnings
- —
About China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.
- ISIN
- CNE0000011K8
- Founded
- 1999
- Listed since
- Mar 9, 2000
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.